Patents by Inventor Andrew Paul Combs

Andrew Paul Combs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CDK inhibitors and their use as pharmaceuticals
    Patent number: 12129262
    Abstract: The disclosure is directed to compounds of Formula I pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: October 29, 2024
    Assignee: Prelude Therapeutics Incorporated
    Inventors: Xiaowei Wu, Andrew W. Buesking, Andrew Paul Combs, Ryan Holmes, Sarah Pawley, Katarina Rohlfing
  • BRM Targeting Compounds And Associated Methods Of Use
    Publication number: 20240336612
    Abstract: The present disclosure provides bifunctional compounds comprising a target protein binding moiety and a E3 ubiquitin ligase binding moiety, and associated methods of use.
    Type: Application
    Filed: July 12, 2022
    Publication date: October 10, 2024
    Inventors: Liang Lu, Andrew Paul Combs
  • BRM Targeting Compounds and Associated Methods of Use
    Publication number: 20240190886
    Abstract: The present disclosure provides bifunctional compounds comprising a target protein binding moiety and a E3 ubiquitin ligase binding moiety, and associated methods of use.
    Type: Application
    Filed: November 14, 2023
    Publication date: June 13, 2024
    Inventors: Corey Howard Basch, Song Mei, Liang Lu, Artem Shvartsbart, Andrew Paul Combs, Sina Rezazadeh
  • BRM Targeting Compounds And Associated Methods Of Use
    Publication number: 20240165244
    Abstract: The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
    Type: Application
    Filed: September 15, 2023
    Publication date: May 23, 2024
    Inventors: Corey Howard Basch, Song Mei, Liang Liu, Artem Shvartsbart, Andrew Paul Combs, John A. Rose, Klare L. Bersch, Sina Rezazadeh, Vijayarajan Devannah, Danielle Beam Roth
  • BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE
    Publication number: 20240018158
    Abstract: The present disclosure provides bifunctional compounds comprising a target protein binding moiety and a E3 ubiquitin ligase binding moiety, and associated methods of use.
    Type: Application
    Filed: May 15, 2023
    Publication date: January 18, 2024
    Inventors: Hong Lin, Philip Pitis, Liang Lu, Andrew Paul Combs
  • BRM Targeting Compounds And Associated Methods Of Use
    Publication number: 20230365576
    Abstract: The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
    Type: Application
    Filed: May 9, 2023
    Publication date: November 16, 2023
    Inventors: John A. Rose, Corey Howard Basch, Song Mei, Klare Lazor Bersh, Danielle Roth, Katarina Rohlfing, Xiaowei Wu, Artem Shvartsbart, Andrew Paul Combs, Liang Lu
  • SPIRO-SULFONAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN
    Publication number: 20230357275
    Abstract: The disclosure is directed to crystalline forms of the compound of Formula I: Formula (I), and pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprising compounds of Formula I as well as methods of their use and preparation, are also described.
    Type: Application
    Filed: May 13, 2021
    Publication date: November 9, 2023
    Inventors: Jincong Zhuo, Ganfeng Cao, Andrew Paul Combs, Qun Li, Huaping Zhang
  • CDK Inhibitors And Their Use As Pharmaceuticals
    Publication number: 20230357265
    Abstract: The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
    Type: Application
    Filed: March 16, 2023
    Publication date: November 9, 2023
    Inventors: Andrew W. Buesking, Andrew Paul Combs, Jincong Zhou, Ryan Holmes, Sarah Pawley, Xiaowei Wu
  • CDK Inhibitors And Their Use As Pharmaceuticals
    Publication number: 20230242543
    Abstract: The disclosure is directed to, in part, to CDK inhibitors, pharmaceutical compositions comprising the same, as well as methods of their use and preparation.
    Type: Application
    Filed: April 4, 2023
    Publication date: August 3, 2023
    Inventors: Liang Lu, Rupa Shetty, Andrew Paul Combs, Chaofeng Dai, Raul Andrew Leal, Klare Lazor Bersch
  • BRM targeting compounds and associated methods of use
    Patent number: 11702423
    Abstract: The present disclosure provides bifunctional compounds comprising a target protein binding moiety and a E3 ubiquitin ligase binding moiety, and associated methods of use.
    Type: Grant
    Filed: June 9, 2021
    Date of Patent: July 18, 2023
    Assignee: Prelude Therapeutics Incorporated
    Inventors: Hong Lin, Philip Pitis, Liang Lu, Andrew Paul Combs
  • SPIRO-SULFONIMIDAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN
    Publication number: 20230212191
    Abstract: The disclosure is directed to compounds of Formula (I). Pharmaceutical compositions comprising compounds of Formula (I) as well as methods of their use and preparation, are also described.
    Type: Application
    Filed: April 16, 2021
    Publication date: July 6, 2023
    Applicant: PRELUDE THERAPEUTICS, INCORPORATED
    Inventors: Jincong ZHUO, Andrew Paul COMBS
  • CDK inhibitors and their use as pharmaceuticals
    Patent number: 11685744
    Abstract: The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
    Type: Grant
    Filed: September 21, 2021
    Date of Patent: June 27, 2023
    Assignee: Prelude Therapeutics Incorporated
    Inventors: Andrew W. Buesking, Andrew Paul Combs, Jincong Zhuo, Ryan Holmes, Sarah Pawley, Xiaowei Wu
  • CDK inhibitors and their use as pharmaceuticals
    Patent number: 11673893
    Abstract: The disclosure is directed to, in part, to CDK inhibitors, pharmaceutical compositions comprising the same, as well as methods of their use and preparation.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: June 13, 2023
    Assignee: Prelude Therapeutics Incorporated
    Inventors: Liang Lu, Rupa Shetty, Andrew Paul Combs, Chaofeng Dai, Raul Andrew Leal, Klare Lazor Bersch
  • CDK Inhibitors And Their Use As Pharmaceuticals
    Publication number: 20230144528
    Abstract: The disclosure is directed to, in part, to CDK inhibitors, pharmaceutical compositions comprising the same, as well as methods of their use and preparation.
    Type: Application
    Filed: September 30, 2022
    Publication date: May 11, 2023
    Inventors: Liang Lu, Rupa Shetty, Andrew Paul Combs, Chaofeng Dai, Raul Andrew Leal, Klare Lazor Bersch
  • BCL-2 inhibitors and their use as pharmaceuticals
    Patent number: 11622970
    Abstract: The disclosure is directed to, in part, to BCL-2 inhibitors, pharmaceutical compositions comprising the same, as well as methods of their use and preparation.
    Type: Grant
    Filed: April 27, 2021
    Date of Patent: April 11, 2023
    Assignee: Prelude Therapeutics Incorporation
    Inventors: Jincong Zhuo, Andrew Paul Combs, Peng Wei, Jialiang Wang
  • BRM Targeting Compounds And Associated Methods Of Use
    Publication number: 20230083376
    Abstract: The present disclosure provides bifunctional compounds comprising a target protein binding moiety and a E3 ubiquitin ligase binding moiety, and associated methods of use.
    Type: Application
    Filed: November 8, 2021
    Publication date: March 16, 2023
    Inventors: Liang Lu, Andrew Paul Combs, Corey Howard Basch, Rupa Shetty, Chaofeng Dai, Klare Lazor Bersch, John A. Rose, Danielle Julie Beam, Song Mei
  • Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein
    Publication number: 20230010358
    Abstract: The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I as well as methods of their use and preparation, are also described.
    Type: Application
    Filed: August 17, 2021
    Publication date: January 12, 2023
    Inventors: Jincong Zhuo, Raul Leal, Rupa Shetty, Juan Luengo, Andrew Paul Combs, Peng Wei
  • CDK Inhibitors And Their Use As Pharmaceuticals
    Publication number: 20220324830
    Abstract: The disclosure is directed to, in part, to CDK inhibitors, pharmaceutical compositions comprising the same, as well as methods of their use and preparation.
    Type: Application
    Filed: September 11, 2020
    Publication date: October 13, 2022
    Inventors: Liang Lu, Rupa Shetty, Andrew Paul Combs, Chaofeng Dai, Raul Andrew Leal, Klare Lazor Bersch
  • CDK Inhibitors And Their Use As Pharmaceuticals
    Publication number: 20220267345
    Abstract: The disclosure is directed to compounds of Formula I pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
    Type: Application
    Filed: December 17, 2021
    Publication date: August 25, 2022
    Inventors: Xiaowei Wu, Andrew W. Buesking, Andrew Paul Combs, Ryan Holmes, Sarah Pawley, Katarina Rohlfing
  • CDK Inhibitors And Their Use As Pharmaceuticals
    Publication number: 20220089608
    Abstract: The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
    Type: Application
    Filed: September 21, 2021
    Publication date: March 24, 2022
    Inventors: Andrew W. Buesking, Andrew Paul Combs, Jincong Zhou, Ryan Holmes, Sarah Pawley, Xiaowei Wu